Zynamite has been shown to have ergogenic and nootropic properties that enable early mental activation; better mental and physical performance; and dramatic increases in peak power, mean power output, VO 2 max, muscle oxygen utilisation and brain oxygenation
Based on its recent analysis of the European sports nutrition and health ingredients market, Frost & Sullivan has recognised Spain-based Nektium Pharma with the 2019 European New Product Innovation Award for its already award winning novel natural botanical extract, Zynamite.
This product has demonstrated significant ergogenic and nootropic properties including faster reaction time and better mental and physical performance. It is a safe, doping free and sustainable alternative to caffeine, with nutritional benefits that are superior to those of competing natural extracts.
"Nektium launched the novel, patent-pending Mangifera indica extract, Zynamite, which is derived from mango leaves and composed of 60% mangiferin, a xanthone. It has been shown to have ergogenic and nootropic properties that enable early mental activation; better mental and physical performance; and dramatic increases in peak power, mean power output, VO 2 max, muscle oxygen utilisation, and brain oxygenation. It is also an inhibitor of catechol-O-methyltransferase, or COMT, which has anti-addictive potential," said Smriti Sharma, industry analyst. "While other companies too have developed novel herbal or plant-based nootropic agents, none offer the combination of benefits that Zynamite does."
Its strong patent portfolio, with three pending patents for different attributes of the mangiferin extract, protects its first-mover advantage. Nektium showed that the activation mechanism of Zynamite on the central nervous system is different to that of caffeine but with a surprisingly similar effect, which gives it an edge over other key natural extracts. Furthermore, unlike caffeine, Zynamite has shown no negative side effects among users.